Cited by 66Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesRegulation of Appetite and Obesity

Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications

Open access
Garvey, W. Timothy·2022·Endocrine Practice

Abstract

Adiposity-based chronic disease (ABCD) requires life-long treatment and follow up. Obesity protects obesity through altered regulation of caloric intake and set point mechanisms, which help maintain a high equilibrium body weight. Lifestyle interventions and obesity medications do not permanently alter the set point, which often makes weight loss achieved using lifestyle changes short-lived and operates to drive weight regain once medications are discontinued. Bariatric surgery procedures can alter appetite and lower the "set point" for the equilibrium body weight via unknown mechanisms. However, few patients attain an ideal body weight following surgery, many regain weight, and all require long-term follow up for the disease. The excess adiposity associated with ABCD gives rise to complications that impair health and confer morbidity and mortality; however, the genetic risks and potential interactions between genes and the environment that give rise to complications cannot be eliminated. The equilibrium body weight around which set point mechanisms operate can be modified by the environment, which underscores the importance of a less obesogenic environment for the prevention and treatment of ABCD on a population basis. Whether ABCD will eventually be curable will depend on a clear understanding of the molecular mechanisms that determine the set point regulation of body weight and the ability to permanently modulate the set point to oscillate around a lean body mass. However, the conceptualization of ABCD as a chronic disease does present us with opportunities for primary, secondary, and tertiary prevention to avert disease progression. For tertiary care, the advent of new, more effective second-generation obesity medications will allow clinicians to treat to target via active management of body weight into a target range that will ameliorate specific complications.

Integrity signals

Registry

Crossref · 10.1016/j.eprac.2021.11.082

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The equilibrium body weight is fiercely defended by the brain, regardless of whether this set point represents a so-called healthy weight or an excessive degree of body fat in people with overweight or obesity.

    “The equilibrium body weight is fiercely defended by the brain, regardless of whether this set point represents a so-called healthy weight or an excessive degree of body fat in people with overweight or obesity.89”

    From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [89]

The citation lists haven’t been fetched yet

References 73 · Cited by 66

Authors
Garvey, W. T.
Affiliations
University of Alabama at Birmingham (US)
Corresponding author
Garvey, W. Timothy
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2022-02
Volume
28
Issue
2
Pages
214-222
ISSN
1530-891X (ISSN-L)
OpenAlex
W3217411009
Cited by
66
References
73
Citations by year
2026: 13 · 2025: 22 · 2024: 11 · 2023: 12 · 2022: 7 · 2021: 1
FWCI
0.98
Type
journal article
Language
en
Open access
Locations
  • Endocrine Practice (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (P30 DK079626)
  • American Heart Association Inc
  • Eli Lilly and Company
  • Pfizer
  • Boehringer Ingelheim
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, set-point theory, weight regain, anti-obesity drugs, bariatric surgery, lifestyle intervention, obesogenic environment, gene-environment interaction, obesity prevention, chronic disease management, weight management
MeSH terms
Energy Intake, Chronic Disease, Humans, Obesity, Weight Loss, Adiposity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review